Tag: Pomalyst

As of early 2022, a generic version of Revlimid (lenalidomide) became available, offering a potential lower-cost alternative to the brand-name drug. For patients exploring the question, 'Is there a substitute for Revlimid?', the answer extends beyond generics to include an expanding range of therapies for conditions like multiple myeloma and myelodysplastic syndromes.

First approved by the FDA in 2013, Pomalyst (pomalidomide) is a third-generation immunomodulatory drug used to treat certain cancers, primarily multiple myeloma. This article explores the complex, multi-faceted mechanisms behind **how does the Pomalyst work** to fight cancer.